TLDR:
- Abolis Biotechnologies, based in France, raised €35M in funding with backing from various investors.
- The company plans to use the funds to expand globally and further develop its bioproduction solutions.
Abolis Biotechnologies, a company specializing in industrial solutions using microorganisms based in Évry-Courcouronnes, France, has successfully raised €35M in funding. The funding round included investments from L’Oréal’s venture capital fund BOLD, DeepTech & Climate Fonds, and Evonik Venture Capital, among others. The company, led by CEO Cyrille Pauthenier, plans to use the funds to accelerate its expansion into global markets and further develop its research and development efforts.
Abolis Biotechnologies combines expertise in biology, fermentation, IT, robotics, analytics, and industrial property to innovate various industries, from food to healthcare, cosmetics, and chemicals. They leverage biotechnologies and the potential of microorganisms to develop bioproduction solutions that are economically and ecologically sustainable alternatives to petrochemical products and chemical ingredients.
The investment in Abolis Biotechnologies also marked the signing of a new strategic industrial partnership between the company, L’Oréal, and Evonik to bring selected innovations to market in the healthcare, cosmetic, and chemical sectors. This partnership aims to further drive innovation and bring new products to the market.
